Zimbabwe has turned down a substantial US health deal worth $367m (272 million pounds) over five years due to the United States' request for sensitive data.
This move came to light following a internal memorandum dated December was leaked, revealing that President Emmerson Mnangagwa felt the deal was "skewed".
A government spokesman later explained that the United States was requesting genetic material for research and commercial purposes while was not willing to share the resulting advantages from future medical innovations.
"We must now begin the difficult and regrettable task of ending our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had donated over $1.9bn for health programmes to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has appealed for more dialogue to find a deal suitable to all parties so the country's vital HIV treatment initiative can be sustained.
Broader Implications
Zimbabwe's decision comes after a similar situation in neighbouring Kenya, where a high court blocked a related deal with the US following legal challenges were raised about the safety of Kenyans' medical information.
After resuming office recently, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
USAID had overseen assistance for the US government, but Trump claimed its expenditure was "inefficient" and his administration was seeking direct bilateral agreements to boost transparency and responsibility.
As per reports, Sixteen African countries have so far agreed to these new agreements, constituting more than $18.3bn in committed funds.
Details of the Declined Agreement
The funds for Zimbabwe was intended to supported "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this collaboration could have provided immense advantages for the people of Zimbabwe, particularly the 1.2 million presently on HIV treatment via US-supported programmes," Tremont added.
However, government spokesperson Nick Mangwana said the arrangement was "unequal".
"Our nation was requested to surrender its genetic material and health information over an extended period, without any equivalent guarantee of access to any medical innovations – like new medicines or tests – that could result from that shared data," his statement read.
"Effectively, our country would provide the basic resources for scientific discovery with no certainty that the resulting innovations would be accessible to our citizens should a future pandemic emerge."
National Interest and Global Health
He also noted that the American exit from the global health body and its push of bilateral deals were upending structures previously set up through the global organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme designed to deal with future global health emergencies.
"This mechanism is intended to guarantee that when a country provides its samples, the benefits – such as vaccines and treatments – are shared equitably, not commercialised solely by those with the capability to develop them."
Zimbabwe's reservations regarding the US deal "are not meant as opposition to America," Mangwana stressed.
"We welcome further dialogue with our American counterparts on how subsequent collaboration could be designed in a way that honours the sovereignty and interests of each country."
Health Experts Response
A leading public health body said it acknowledged the official position, but urged that negotiations need to persist considering much of the nation's HIV programmes were funded by foreign aid.
"In cases where technical issues arise, such as those involving data governance or implementation frameworks, these can frequently be addressed through detailed discussion and mutually agreed protections," the group commented.
The situation highlights the complex tensions between accepting vital foreign assistance and protecting national sovereignty in an ever more data-driven world.